24 April 2020 - Stem cell-focused biotech Mesoblast has claimed a breakthrough in its experimental therapy to treat patients with potentially lethal coronavirus complications, reporting a significant increase in survival rates after a fortnight of testing.

The Anthony Pratt and Thorney Investment-backed company has begun a clinical trial in the US, with the support of the National Institutes of Health, to test whether its new therapy remestemcel-L can fight COVID-19.

Mesoblast reported on Friday that after two weeks of testing, it had recorded an 83% survival rate in ventilator-dependent COVID-19 patients, while 75% of patients have successfully come off ventilator support within 10 days.

Read The Australian article